Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.

被引：0
|
作者：
Pant, Shubham
Schuler, Martin H.
Iyer, Gopa
Witt, Olaf
Doi, Toshihiko
Qin, Shukui
Tabernero, Josep
Reardon, David A.
Massard, Christophe
Welsh, Liam
Lugowska, Iwona A.
Carranza, Omar
Stuyckens, Kim
Liao, Huimin
Najmi, Saltanat
Hammond, Constance
Thomas, Shibu
Triantos, Spyros
Sweiti, Hussein
Loriot, Yohann
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Heidelberg Hosp, Hopp Childrens Canc Ctr KiTZ, German Canc Res Ctr Heidelberg, Heidelberg, Germany
[5] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany
[6] Natl Canc Ctr Hosp East, Chiba, Japan
[7] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[10] Dana Farber Canc Inst, Boston, MA USA
[11] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[12] Royal Marsden NHS Fdn Trust, London, England
[13] Narodowy Instytut Onkologii, Marii Sklodowskiej Curie Panstwowy Inst Badawczy, Warsaw, Poland
[14] Hosp Privado Comunidad Mar Plata, Mar Del Plata, Argentina
[15] Janssen Res & Dev, Beerse, PA, Belgium
[16] Janssen Res & Dev, Shanghai, Peoples R China
[17] Janssen Res & Dev, Spring House, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3121
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations.
    Pant, Shubham
    Tabernero, Josep
    Massard, Christophe
    Iyer, Gopa
    Witt, Olaf
    Doi, Toshihiko
    Qin Shukui
    Lu-Emerson, Christine
    Hargrave, Darren R.
    Garcia-Corbacho, Javier
    Little, Shonda Marie
    Xia, Qi
    Santiago-Walker, Ademi E.
    Moy, Christopher
    Hammond, Constance
    Sweiti, Hussein
    Schuler, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [42] SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations
    Loriot, Y.
    Necchi, A.
    Hussain, S. A.
    De Velasco Oria, G. A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1163 - S1164
  • [43] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Segal, Neil Howard
    Girda, Eugenia
    Sohal, Davendra
    Lakhani, Nehal J.
    Olszanski, Anthony J.
    Fong, Lawrence
    Kinnaman, Michael David
    Han, Hyunsil
    Skokos, Dimitris
    Casey, Kerry A.
    Wang, JuAn
    Wang, Bei
    Hao, Yi
    Li, Siyu
    Ganguly, Samit
    Lowy, Israel
    Seebach, Frank A.
    Mathias, Melissa Divya
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
    Schoenfeld, Adam Jacob
    Warner, Allison Betof
    Chesney, Jason Alan
    Thomas, Sajeve Samuel
    Hamid, Omid
    In, Gino Kim
    Shoushtari, Alexander Noor
    Samhouri, Yazan
    Hari, Parameswaran N.
    Ramsingh, Giridharan
    Renard, Camille
    Prabhakar, Prakash
    Mclaughlin, Lauren
    He, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
    Grana, B.
    Burris, H. A.
    Ahnert, J. Rodon
    Razak, A. R. Abdul
    De Jonge, M. J.
    Eskens, F.
    Siu, L. L.
    Ru, Q. C.
    Homji, N. F.
    Demanse, D.
    Di Tomaso, E.
    Cosaert, J. G. C. E.
    Quadt, C.
    Baselga, J.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.
    Dummer, Reinhard
    Migden, Michael Robert
    Guminski, Alexander
    Gutzmer, Ralf
    Kudchadkar, Ragini Reiney
    Lewis, Karl D.
    Dirix, Luc
    Combemale, Patrick
    Trefzer, Uwe
    Loquai, Carmen
    Kaatz, Martin
    Chang, Anne L. S.
    Stratigos, Alexander
    Plummer, Elizabeth R.
    Mone, Manisha
    Castro, HenryJ.
    Yi, Tingting
    Sellami, Dalila B.
    Lear, John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2
    Liu, Stephen V.
    Peeters, Marc
    Ahn, Myung-Ju
    Lin, Jessica J.
    Ohe, Yuichiro
    Yau, Chung Cheung Thomas
    Bordogna, Walter
    Osborne, Stuart
    Schwemmers, Sven
    Zeuner, Harald
    Goto, Koichi
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [48] Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
    Zhang, P.
    Gong, J.
    Guo, H.
    Han, W.
    Cao, B.
    Zhang, J.
    Niu, Z.
    Cheng, Y.
    He, C.
    Fan, J.
    Peng, P.
    Sun, C.
    Wang, H.
    Yu, Y.
    Zhu, Y.
    Wu, Y.
    Li, Q.
    Huang, P.
    Wu, F.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S471 - S471
  • [49] Trial in Progress: A Phase 1/2 Study to Investigate the Safety and Efficacy of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients (Pts) with Advanced Solid Tumors
    Schoenfeld, Adam J.
    Warner, Allison Betof
    Thomas, Sajeve S.
    Hamid, Omid
    In, Gino K.
    Shoushtari, Alexander N.
    Samhouri, Yazan
    Hari, Parameswaran
    Ramsingh, Giridharan
    Prabhakar, Prakash
    Mclaughlin, Lauren
    Chesney, Jason A.
    MOLECULAR THERAPY, 2024, 32 (04) : 881 - 881
  • [50] Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.
    Li, Bob T.
    Li, Tianhong
    Johnson, Melissa Lynne
    Waqar, Saiama Naheed
    Zhu, Viola Weijia
    Ou, Sai-Hong Ignatius
    Lin, Jessica Jiyeong
    Wang, Ding
    Shapiro, Geoffrey
    Wang, Judy Sing-Zan
    Liu, Dazhi
    Ye, Yuqing
    Kosar, Hana
    Hee, Angela
    Berk, Greg
    Zhang, Sean
    Wang, Junsheng
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345